The simple frontend has all the same abilities to set the properties.
<simple:server …>
<simple:properties>
<entry.../>
If you are using code, the ServerFactoryBean has properties maps on it as well.
Dan
On Sep 12, 2012, at 10:57 AM, Vassilis Virvilis <[email protected]> wrote:
> Hi everybody,
>
> I am upgrading to CXF 2.6.2 but for some clients I am getting
> Caused by: org.apache.ws.security.WSSecurityException: An error was
> discovered processing the <wsse:Security> header (An error happened
> processing a Username Token "A replay attack has been detected")
> at
> org.apache.ws.security.processor.UsernameTokenProcessor.handleUsernameToken(UsernameTokenProcessor.java:140)
> at
> org.apache.ws.security.processor.UsernameTokenProcessor.handleToken(UsernameTokenProcessor.java:66)
> at
> org.apache.ws.security.WSSecurityEngine.processSecurityHeader(WSSecurityEngine.java:396)
> at
> org.apache.cxf.ws.security.wss4j.WSS4JInInterceptor.handleMessage(WSS4JInInterceptor.java:284)
>
> So it looks like I have to disable the nonce cache just like in bug
> https://issues.apache.org/jira/browse/CXF-4294
>
> However I am not using jax-ws. I am using simple frontend with spring
> configuration so I can't use following snippet
>
> <jaxws:endpoint id="....">
> ...
> <jaxws:properties>
> ...
> <entry key="ws-security.enable.nonce.cache" value="false" />
> <entry key="ws-security.enable.timestamp.cache" value="false" />
> </jaxws:properties>
> </jaxws:endpoint>
>
>
> Any ideas what is the correct XML configuration or it is not possible to turn
> this thing off with JAX_WS?
>
> Thanks in advance
>
> --
>
> __________________________________
>
> Vassilis Virvilis Ph.D.
> Head of IT
> Biovista Inc.
>
> US Offices
> 2421 Ivy Road
> Charlottesville, VA 22903
> USA
> T: +1.434.971.1141
> F: +1.434.971.1144
>
> European Offices
> 34 Rodopoleos Street
> Ellinikon, Athens 16777
> GREECE
> T: +30.210.9629848
> F: +30.210.9647606
>
> www.biovista.com
>
> Biovista is a privately held biotechnology company that finds novel uses for
> existing drugs, and profiles their side effects using their mechanism of
> action. Biovista develops its own pipeline of drugs in CNS, oncology,
> auto-immune and rare diseases. Biovista is collaborating with
> biopharmaceutical companies on indication expansion and de-risking of their
> portfolios and with the FDA on adverse event prediction.
>
>
--
Daniel Kulp
[email protected] - http://dankulp.com/blog
Talend Community Coder - http://coders.talend.com
